Viking Therapeutics has announced positive results from its Phase Ib trial of VK0214 in patients with X-linked ...

Chicago-based Vanqua Bio’s Parkinson’s disease drug has shown proof-of-concept in a first-in-human study, with the company to ...

InnoCare Pharma has announced that its Phase II study of the TYK2 inhibitor ICP-488 for psoriasis treatment met the primary ...

Priovant expects topline data from two Phase III trials for its dual TYK2 and Jak1 inhibitor in dermatomyositis and uveitis ...

DiaMedica Therapeutics has received the SAHPRA approval to commence a Phase II trial of DM199 to treat preeclampsia.

Gamifying clinical trials could motivate participants to engage better with trial platforms and advance research.

Allurion has added more efficacy and safety data to support its intragastric balloon, but popularity of GLP-1 drugs shows no ...

Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead candidate PS-002 to ...

Cassava alleged that the short sellers had launched a “short and distort” campaign which caused a “decline in Cassava ...

The company plans to study the application of molecular residual disease (MRD) testing in breast cancer management using its ...

KaliVir Immunotherapeutics has dosed the first subject in a Phase I/Ib trial of VET3-TGI to treat incurable advanced solid ...

Scholar Rock’s stock price increased by 362% after the company announced data from the Phase III SAPPHIRE trial of ...